EXPLORE THE SCIENCE
TL;DR: A 2026 randomized controlled study in Pakistan Journal of Pharmaceutical Sciences found that adding 20 Hz repetitive transcranial magnetic stimulation (rTMS) to risperidone was linked with lower cognitive-factor and aggression scores after 4 weeks in sc…
Read article
TL;DR: A 2026 study in Health Science Reports found that metoclopramide and several antipsychotics were strongly overrepresented in FDA adverse-event reports for drug-induced dystonia, with many reported cases appearing within the first month after drug initia…
Read article
TL;DR: A 2026 study in Clinical Case Reports described persistent genital arousal disorder in a woman in her 30s, with symptom improvement after combined risperidone, sodium valproate, fluoxetine, short-term clonazepam, relaxation work, and cognitive behaviora…
Read article
TL;DR: A 2026 population-based matched cohort study in British Journal of Psychiatry found that risperidone use was associated with increased stroke risk, adjusted hazard ratio 1.28, while absolute stroke incidence was especially high in people with prior stro…
Read article
TL;DR: A 2026 randomized phase 2b trial in Journal of Clinical Psychopharmacology found that the PDE10A inhibitor MK-8189 did not improve Positive and Negative Syndrome Scale (PANSS) schizophrenia symptom scores more than placebo after 6 weeks, while risperido…
Read article
Antipsychotic medications are commonly used to treat psychotic disorders like schizophrenia and bipolar disorder. However, these drugs often cause side effects like elevated prolactin levels, which can negatively impact long-term health. A new study analyzed m…
Read article